Joon Oh Park

30.7k total citations · 9 hit papers
387 papers, 16.2k citations indexed

About

Joon Oh Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Joon Oh Park has authored 387 papers receiving a total of 16.2k indexed citations (citations by other indexed papers that have themselves been cited), including 263 papers in Oncology, 181 papers in Pulmonary and Respiratory Medicine and 140 papers in Surgery. Recurrent topics in Joon Oh Park's work include Pancreatic and Hepatic Oncology Research (92 papers), Colorectal Cancer Treatments and Studies (92 papers) and Gastric Cancer Management and Outcomes (86 papers). Joon Oh Park is often cited by papers focused on Pancreatic and Hepatic Oncology Research (92 papers), Colorectal Cancer Treatments and Studies (92 papers) and Gastric Cancer Management and Outcomes (86 papers). Joon Oh Park collaborates with scholars based in South Korea, United States and United Kingdom. Joon Oh Park's co-authors include Won Ki Kang, Jeeyun Lee, Ho Yeong Lim, Se Hoon Park, Young Suk Park, Pasi A. Jänne, Neal I. Lindeman, Xiao‐Jun Zhao, Kreshnik Zejnullahu and Tony Mok and has published in prestigious journals such as Science, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Joon Oh Park

374 papers receiving 15.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

2015 634 citations Joon Oh Park, Baek‐Yeol Ryoo et al. profile →
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations Joon Oh Park et al. profile →
Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial

2011 560 citations Jeeyun Lee, Do Hoon Lim et al. Journal of Clinical Oncology profile →
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

2012 474 citations Jeeyun Lee, Joon Oh Park et al. Journal of Clinical Oncology profile →
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

2018 467 citations Do‐Youn Oh, Joon Oh Park et al. profile →
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses

2015 297 citations Se Hoon Park, Tae Sung Sohn et al. Journal of Clinical Oncology profile →
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

2021 171 citations Funda Meric‐Bernstam, Rastislav Bahleda et al. Cancer Discovery profile →
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

2024 43 citations Funda Meric‐Bernstam, Do‐Youn Oh et al. profile →

Peers

Countries citing papers authored by Joon Oh Park

Since Specialization

Citations

This map shows the geographic impact of Joon Oh Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joon Oh Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joon Oh Park more than expected).

Fields of papers citing papers by Joon Oh Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joon Oh Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joon Oh Park. The network helps show where Joon Oh Park may publish in the future.

Co-authorship network of co-authors of Joon Oh Park

This figure shows the co-authorship network connecting the top 25 collaborators of Joon Oh Park. A scholar is included among the top collaborators of Joon Oh Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joon Oh Park. Joon Oh Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis. 2024 ·Journal of Clinical Oncology ·Christopher J. Burns, Terrie‐Anne Cock, Anthony C. Bishop, (unknown), (unknown), Sumitra Ananda, Marion Harris, Warren Joubert, Jin Won Kim, Choong‐kun Lee, Woo Jin Lee, (unknown), Adnan Nagrial, Do-Youn Oh, Joon Oh Park, Nick Pavlakis, Jason D. Lickliter	1
2	Updated safety, efficacy, pharmacokinetics, and biomarkers from the phase 1 study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Ho Yeong Lim, Jin Seok Ahn, Joon Oh Park, Jung Yong Hong, Sungyoung Lee, (unknown), Hwi‐yeol Yun, Seung‐Hwan Shin, Chan‐Young Ock, (unknown)	2
3	Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies. 2024 ·Journal of Clinical Oncology ·Shubham Pant, Joon Oh Park, Wu‐Chou Su, Martin Schüler, (unknown), Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Gunnar Folprecht, Helen Winter, Graziela Zibetti Dal Molin, Hussein Sweiti, (unknown), Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin‐Hsun Feng	1
4	Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study 2023 ·Journal of the National Comprehensive Cancer Network ·Joo‐Hyun Park, Jung Yong Hong, Jay J. Shen, Kyungdo Han, (unknown), Joon Oh Park	9
5	1035P Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors 2023 ·Annals of Oncology ·Ho Yeong Lim, Jin Seok Ahn, Joon Oh Park, Jung Yong Hong, Hyun Ju Seon, (unknown), (unknown), (unknown)	1
6	1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Alison M. Schram, Kōichi Goto, Dongwook Kim, Antoine Hollebecque, Sun Young Rha, Kazumi Nishino, M. Duruisseaux, (unknown), Joon Oh Park, Natasha B. Leighl, Teresa Macarulla, Stephen V. Liu, Mohammed Najeeb Al Hallak, James M. Cleary, Cindy Neuzillet, Yasushi Goto, Andrew K. Joe, (unknown), (unknown), Alexander Drilon	10
7	Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer 2023 ·Science Advances ·Sujin Hyung, Jihoon Ko, You Jeong Heo, Steven M. Blum, Seung Tae Kim, Se Hoon Park, Joon Oh Park, Won Ki Kang, Ho Yeong Lim, Samuel J. Klempner, Jeeyun Lee	36
8	Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer 2022 ·Journal of Clinical Oncology ·Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan	120
9	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer 2021 ·Clinical Cancer Research ·Seung Tae Kim, Simon A. Smith, Peter G. Mortimer, Arsène‐Bienvenu Loembé, (unknown), Kyoung‐Mee Kim, Claire Smith, Sophie E. Willis, Itziar Irurzun‐Arana, Aliénor Berges, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Iwanka Kozarewa, Andrew J. Pierce, Emma Dean, Jeeyun Lee	61
10	Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study breakdown → 2021 ·Cancer Discovery ·Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal	171
11	Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) 2021 ·Journal of Clinical Oncology ·J. Randolph Hecht, Sara Lonardi, Johanna C. Bendell, Hao‐Wen Sim, Teresa Macarulla, Charles D. Lopez, Eric Van Cutsem, Andrés J. Muñoz Martín, Joon Oh Park, Richard Greil, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, Yong Lin, Sujata Rao, Baek‐Yeol Ryoo	78
12	Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population-based cohort study 2021 ·European Journal of Cancer ·Joo‐Hyun Park, (unknown), Jung Yong Hong, Young Shin Park, Gunseog Kang, Kyungdo Han, Joon Oh Park	5
13	Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib 2019 ·Annals of Oncology ·P. Hammel, Hedy L. Kindler, Michele Reni, Eric Van Cutsem, Teresa Macarulla, C. Michael Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do‐Youn Oh, Anke Reinacher‐Schick, Giampaolo Tortora, Hana Algül, Eileen M. O’Reilly, David McGuinness, Karen Cui, (unknown), (unknown), Nikunj Patel, Talia Golan	33
14	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial 2018 ·Journal of the Korean Gastric Cancer Association ·(unknown), Kyoung‐Mee Kim, Min Gew Choi, Jun Ho Lee, Tae Sung Sohn, Jae-Moon Bae, (unknown), Su Jin Lee, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park	9
15	Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients 2015 ·Oncotarget ·Seung Tae Kim, Won‐Suk Lee, Richard B. Lanman, Stefanie Mortimer, Oliver A. Zill, Kyoung-Mee Kim, Kee Taek Jang, Seok Hyung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Helmy Eltoukhy, Won Ki Kang, Woo Yong Lee, Hee‐Cheol Kim, Keunchil Park, Jeeyun Lee, AmirAli Talasaz	63
16	Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification 2014 ·Molecular Cancer Therapeutics ·Seung Tae Kim, (unknown), Su Jin Lee, Jeeyun Lee, Yoon‐La Choi, Kyoung‐Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, Joon Oh Park	35
17	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial breakdown → 2011 ·Journal of Clinical Oncology ·Jeeyun Lee, Do Hoon Lim, Sung Kim, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Min Gew Choi, Tae Sung Sohn, Jae Hyung Noh, Jae Moon Bae, Yong Chan Ahn, Insuk Sohn, Sin Ho Jung, Cheol Keun Park, Kyoung‐Mee Kim, Won Ki Kang	560
18	Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients 2011 ·Cancer ·Hong‐Hee Won, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jong‐Won Kim, Soo‐Youn Lee, Se Hoon Park	73
19	Recent advances of palliative chemotherapy in advanced colorectal cancer 2009 ·The Korean Journal of Internal Medicine ·Joon Oh Park	1
20	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling breakdown → 2007 ·Science ·Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal I. Lindeman, (unknown), Xiao‐Jun Zhao, James G. Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, Pasi A. Jänne	3570

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact